Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Sell
31
XFOR Quote, Financials, Valuation and Earnings
Last price:
$0.30
Seasonality move
:
8.26%
Day range:
$0.29 - $0.30
52-week range:
$0.26 - $1.60
Dividend yield:
0%
P/E ratio:
7.78x
P/S ratio:
--
P/B ratio:
0.97x
Volume:
1.5M
Avg. volume:
1.7M
1-year change:
-69.14%
Market cap:
$58M
Revenue:
--
EPS (TTM):
-$0.08
Analysts' Opinion
-
Consensus RatingX4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.13, X4 Pharmaceuticals has an estimated upside of 818.85% from its current price of $0.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.30.
Fair Value
-
According to the consensus of 3 analysts, X4 Pharmaceuticals has 818.85% upside to fair value with a price target of $3.13 per share.
XFOR vs. S&P 500
-
Over the past 5 trading days, X4 Pharmaceuticals has underperformed the S&P 500 by -1.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
X4 Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
X4 Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter X4 Pharmaceuticals reported revenues of $560K.
Earnings Growth
-
X4 Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter X4 Pharmaceuticals reported earnings per share of -$0.18.
Enterprise value:
-1.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
0.96x
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.94x
Gross Profit (TTM):
--
Return On Assets:
-10.2%
Net Income Margin (TTM):
--
Return On Equity:
-30.6%
Return On Invested Capital:
-14.26%
Operating Margin:
-6160.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $560K | |
| Gross Profit | -- | -- | -- | -- | $333K | |
| Operating Income | -$81.8M | -$107.9M | -$130.9M | -$27.2M | -$34.5M | |
| EBITDA | -$90.7M | -$105.6M | -$7.7M | -$541K | -$34M | |
| Diluted EPS | -$2.82 | -$0.79 | -$0.08 | -$0.01 | -$0.18 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $93.9M | $80.7M | $85.7M | $147.9M | $143M | |
| Total Assets | $133.1M | $120.5M | $113.4M | $173.3M | $178.2M | |
| Current Liabilities | $13.2M | $13.2M | $28.7M | $25.4M | $29.3M | |
| Total Liabilities | $43.4M | $51.8M | $51.6M | $105.7M | $118.5M | |
| Total Equity | $89.7M | $68.7M | $61.8M | $67.6M | $59.6M | |
| Total Debt | $25.5M | $33.7M | $33.4M | $54.3M | $75.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$77.1M | -$87.9M | -$125.7M | -$20.8M | -$34M | |
| Cash From Investing | -$82K | -$10.1M | $70.8M | -$5.2M | -$15.9M | |
| Cash From Financing | $81.2M | $149.1M | $20.3M | $21.2M | -- | |
| Free Cash Flow | -$77.1M | -$87.9M | -$133M | -$20.8M | -$34.1M | |
XFOR
Sector
Market Cap
$58M
$37.4M
Price % of 52-Week High
21.26%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
-0.06%
-0.75%
1-Year Price Total Return
-59.41%
-38.36%
Beta (5-Year)
0.387
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.32
200-day SMA
Sell
Level
$0.62
Bollinger Bands (100)
Sell
Level
0.38 - 0.64
Chaikin Money Flow
Sell
Level
-63.8M
20-day SMA
Sell
Level
$0.38
Relative Strength Index (RSI14)
Sell
Level
34.91
ADX Line
Sell
Level
20.78
Williams %R
Neutral
Level
-73.0933
50-day SMA
Sell
Level
$0.49
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
117.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Stock Forecast FAQ
In the current month, XFOR has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XFOR average analyst price target in the past 3 months is $3.13.
-
Where Will X4 Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that X4 Pharmaceuticals share price will rise to $3.13 per share over the next 12 months.
-
What Do Analysts Say About X4 Pharmaceuticals?
Analysts are divided on their view about X4 Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that X4 Pharmaceuticals is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is X4 Pharmaceuticals's Price Target?
The price target for X4 Pharmaceuticals over the next 1-year time period is forecast to be $3.13 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XFOR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for X4 Pharmaceuticals is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XFOR?
You can purchase shares of X4 Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase X4 Pharmaceuticals shares.
-
What Is The X4 Pharmaceuticals Share Price Today?
X4 Pharmaceuticals was last trading at $0.30 per share. This represents the most recent stock quote for X4 Pharmaceuticals. Yesterday, X4 Pharmaceuticals closed at $0.30 per share.
-
How To Buy X4 Pharmaceuticals Stock Online?
In order to purchase X4 Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
50
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 20
Regencell Bioscience Holdings [RGC] is up 3.38% over the past day.
Buy
82
EXOD alert for Mar 20
Exodus Movement [EXOD] is down 0.61% over the past day.
Sell
50
SRPT alert for Mar 20
Sarepta Therapeutics [SRPT] is down 2.86% over the past day.
